⛏️ Data hunting

PLUS: There's a new AI advisor in town...

New here? Welcome to NAB, and make sure to subscribe to stay informed on the latest developments in AI!

Happy Tuesday, fellow humans 👋

OpenAI continues its data hunting spree, a new AI expert is in town advising big tech and the US government on the power of AI, and healthcare and life science companies are investing heavily in GenAI and LLM tech…

Let’s dive into it!

Have anything you’d like to share with over 40k AI enthusiasts?

🧵 In today's edition:

  • ⛏️ Data hunting

  • 🤔 The newest name in AI

  • 🩺 LLMs in Healthcare

  • 🛠️ AI Tools to Check Out

  • 🤑 AI Fundraising News

  • 🐦 Tweet Post of the Day

⛏️ Data hunting

Source: The Next Web

OpenAI continues its data acquisition journey with a content licensing agreement with the Financial Times.

Here’s the TL;DR:

  • The agreement allows OpenAI to utilize FT's archived content to train their AI models, allowing them to develop GenAI technology to create text, images, and code indistinguishable from human work.

  • The deal permits ChatGPT to provide summaries of FT articles to its global user base of 100 million, with backlinks to the original content on FT.com. This gives ChatGPT access to reliable journalism sources while driving traffic to the Financial Times website.

Why is this important?

  • This is OpenAI's fifth such agreement, following previous deals with the Associated Press, Axel Springer, Le Monde, and Prisa Media.

  • The trend of news publishers entering into licensing agreements is on the rise as AI companies require high-quality data to train their large language models.

  • However, the journey hasn't been entirely smooth. Last year, The New York Times filed a lawsuit against OpenAI and Microsoft, alleging copyright infringement for utilizing NYT articles to build their AI without a license.

As GenAI continues to evolve, striking a balance between tech companies' requirements and protecting content creators' intellectual property remains a consistent negotiation.

Read more: The FT

When discussing leading figures in AI, names like Yann Lecun, Andrej Karpathy, Sam Altman, Geoffrey Hinton, and perhaps Andrew Yang often come to mind.

But in recent times, Ethan Mollick, a professor at the University of Pennsylvania's Wharton School, has become an unlikely AI expert advising the White House, major tech companies like Google and Meta, banks like JPMorgan Chase, and other corporate leaders.

Mollick was an early and obsessive explorer of ChatGPT when it launched in late 2022, sharing findings from experiments with his MBA students. His enthusiasm and early, deep immersion in the technology made him a go-to authority as businesses and policymakers raced to understand AI's implications.

A self-described "rational optimist," Mollick does not charge for behind-the-scenes consulting. But he is in constant demand, on Zoom calls or traveling 2-4 times a week to meet with executives and workers across industries. His contrarian views, like calling Microsoft's new co-pilot AI "dangerous," draw interest.

Mollick and his wife Lilach, who collaborates with him, have built custom AI tools like Devin that foreshadow the next wave of autonomous AI agents acting in the real world. 

The Mollicks are redefining what AI can do in education through simulations and other tools - the new age influencers 📷

Read more: WSJ

A recent survey by John Snow Labs (phenomenal name, 10/10) reveals that the healthcare and life sciences industries are rapidly increasing their investment in GenAI and LLM projects. 

The survey, which involved 304 participants, found that the adoption varied based on roles and the organization's size, with larger companies more likely to evaluate use cases.

Here are some observations:

  • A fifth of technical leaders reported over 300% growth in budgets allocated to GenAI initiatives.

  • While 35% are not yet considering GenAI, approximately 20% are experimenting with these tools without deploying them, and 25% already have GenAI solutions.

  • To facilitate adoption, organizations are investing more in task-specific language models optimized for healthcare use cases than in general-purpose LLMs.

  • The top use cases include responding to patient inquiries, medical chatbots, and information extraction.

  • Accuracy is the top priority when evaluating GenAI tools, followed by security and privacy risks.

  • Major challenges include a lack of accuracy and legal and reputational risks. To mitigate these, 55% are using human-in-the-loop workflows to test and enhance the models.

  • However, many have not thoroughly tested against bias, explainability, and misinformation requirements, and only about a quarter have reported testing for these issues.

Overall: Although interest is high, there are still concerns regarding transparency, patient readiness, and other factors. That said, the healthcare sector sees substantial potential in GenAI as a solution to workforce shortages and burnout.

🛠️ AI Tools to Check Out

  • Boolvideo: Transform blogs, videos, and images into captivating videos with dynamic voices. Check it out!

  • Trickle: Trickle transforms your screenshots using GPT-4 Vision. Beyond summarization, they decode the essence of your captures. Check it out!

  • Mindpal: AI Agents that help you get work done 100x faster. Check it out!

🤑 AI Fundraising News

  • Indigitall raises €6M/$6.4M in Series A funding to provide an AI-powered software platform that allows organizations to communicate with their customers across all incoming and outgoing digital channels and to personalize their messaging campaigns according to the audiences on each channel.

  • Yoneda Labs raises $4M in Seed funding to build a foundation AI chemical manufacturing model for chemists working in drug discovery.

🐦 Tweet Post of the Day

🤔 Hmmmm……

What did you think of today's newsletter?

Login or Subscribe to participate in polls.

And that does it for today's issue.

As always, thanks for reading. Have a great day, and see you next time! ✌️

— Haroon: (definitely) Not A Bot and @haroonchoudery on Twitter

P.S.: Check us out on our socials - snacks on us if you also hit follow. :)

Reply

or to participate.